Principal component analysis of early immune cell dynamics during pembrolizumab treatment of advanced urothelial carcinoma.

Oncol Lett · 2022 · PMC9219027 · PMID 35765279

Europe PMC DOI

hedged sentence

0.1400

closest p · 2.8× alpha

0.1400

boldest claim

The sentences

did not reach statistical significanceP=0.14not close (p > 0.1)

This approach showed that patients in cluster 1 had a relatively poor prognosis, whereas those in cluster 3 tended to have a better prognosis, but these differences did not reach statistical significance in terms of OS and PFS (P=0.14, P=0.78, respectively).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.